Welcome

The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.

Read our FDA Citizen Petition to remove finasteride from the market.

Adverse drug reaction reports worldwide

Adverse drug reaction reports worldwide

PFS research studies published

PFS research studies published

Known suicides worldwide

Known suicides worldwide

Doctors & researchers speaking out

Doctors & researchers speaking out

Nations warning of PFS

Nations warning of PFS

National media reports worldwide

National media reports worldwide

Sources

Patient Services

Connect with other PFS patients

Consult knowledgeable doctors

Report your side effects

Read the latest research

Reminder: Report PFS Symptoms to National Pharmacovigilance Authorities

SOMERSET, N.J., Sept. 9, 2015 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to their respective national pharmacovigilance authorities for inclusion in the World Health Organization Progamme for International Drug Monitoring’s VigiBase database for adverse drug reactions (ADRs). Run by Uppsala Monitoring Centre (UMC), which provides scientific leadership […]

Data Available on Adverse Side Effects of 5α-RIs Don’t Conclusively Suggest They’re Safe, Say Researchers at Boston University School of Medicine

SOMERSET, N.J., Sept. 7, 2015 – Data from preclinical and clinical studies have provided substantial evidence that 5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. These agents interfere with the biosynthesis and […]

Suggestion That Sexual Side Effects Appear Early in Finasteride Therapy then Return to Normal is ‘Inaccurate,’ Say Researchers at Boston University School of Medicine

SOMERSET, N.J., Aug. 26, 2015 – Twenty-five percent of men currently taking finasteride or dutasteride (brand names Proscar and Avodart) for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss are also at risk for adverse events elicited by […]

2015 PFS Foundation Annual Address

Aug. 4, 2015 Dear Friends: By many accounts, we’ve reached a tipping point on post-finasteride syndrome awareness within the medical community. The most significant advancement occurred in March, when the U.S. National Institutes of Health added PFS to its Genetic and Rare Diseases Information Center. “Studies are under way to understand the safety profile of […]

Doctors & Researchers Speaking Out

Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020

Michael S. Irwig, MD, Attending Endocrinologist
Beth Israel Deaconess Medical Center

[A]t least 17 countries…have warned…of the potential for depression, sexual side effects, or both.

Emerging post-marketing reports of persistent depression and sexual side effects have led to growing concerns about the safety of 5α-reductase inhibitors and prompted product labeling changes in many regulatory jurisdictions. Since 2008, at least 17 countries including the United Kingdom and the United States have warned prescribers of the potential for depression, sexual side effects, or both with finasteride.

Post-Finasteride Syndrome: Efforts to explain persistent symptoms are undermined by poor long term data on harms: The BMJ, August 9, 2019

 

Shelly Gray, PharmD, Shirley & Herb Bridge Endowed Professor
University of Washington School of Pharmacy

Two subjects—eight percent—committed suicide during or after the study.

While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.

Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020

Mohit Khera, MD, Director, Laboratory for Andrology Research
Baylor College of Medicine

FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.

Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.

FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000

Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research
US Food and Drug Administration